Impact of drug therapy duration in patients with hepatitis C

American Journal of Pharmacy Benefits

Volumn 4, Issue 6, 2012, Pages

  McCombs, Jeffrey S ^a   Shin, Janet ^a   Hines, Patricia ^b   Saab, Sammy ^a   Yuan, Yong ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b Global Health Economics and Outcomes Research   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPERTENSIVE AGENT; INSULIN; LOOP DIURETIC AGENT; PEGINTERFERON; RIBAVIRIN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; WARFARIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMORBIDITY; DEMOGRAPHY; DRUG COST; GENOTYPE; HEALTH CARE COST; HEALTH HAZARD; HEALTH INSURANCE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; PATIENT COMPLIANCE; PRESCRIPTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNITED STATES;

EID: 84869819532     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. Viral hepatitis: statistics and surveillance. http://www.cdc.gov/hepatitis/Statistics/index.htm. Published 2009. Accessed July 25, 2011.
2. Leigh JP, Bowlus CL, Leistikow BN, Schenker M. Cost of hepatitis C. Arch Intern Med. 2001;161(18):2231-2237.
3. Pyenson B, Fitch K, Iwasaki K. Consequences of hepatitis C virus: cost of a baby boomer epidemic of liver disease. New York, NY: Vertex Pharmaceuticals, Inc. Published May 2009.
4. Wong J, McQuillan G, McHutchison J, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health. 2000; 90(10):1562-1569.
5. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982
6. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-965.
7. Kim AI, Saab S. Treatment of hepatitis C. Am J Med. 2005;118(8):808-815.
8. Mariano A, Caserta C, Pendino GM, et al. Antiviral treatment for hepatitis C virus infection: effectiveness at general population level in a highly endemic area. Dig Liver Dis. 2009;41(7):509-515.
9. Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology. 2008;48(5):1387-1395.
10. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA. 2003;290(2):228-237.
11. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52(3):425-432.
12. Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analysis for current and future treatments of chronic hepatitis C. Value Health. 2011;14(8):1068-1077
13. Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term effectiveness and cost-effectiveness of antiviral treatment in hepatitis C. J Viral Hepat. 2010; 17(1):34-50.
14. Khokhar OS, Lewis JH. Reasons why patients infected with chronic hepatitis C virus choose to defer treatment: do they alter their decision with time? Dig Dis Sci. 2007;52(5):1168-1176.
15. Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen Intern Med. 2005; 20(8)754-758.
16. Evon DM, Ramcharran D, Belle SH, et al. Prospective analysis of depression during peginterferon and ribavirin therapy of chronic hepatitis C: results of the Virahep-C study. Am J Gastroenterol. 2009;104(12):2949-2958.
17. Leutscher PD, Lagging M, Buhl MR, et al. Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 2010;52(2): 430-435.
18. McHutchison JG, Everson GT, Gordon SC, et al; PROVE1 Study Team. Telapre-vir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009;360(18):1827-1838.
19. Kwo P, Lawitz E, McCone J, et al. HCV SPRINT-1 fi nal results: SVR 24 from a phase 2 study of boceprevir plus pegintron (Peginterferon Alfa-2b)/ribavirin in treatment-naive subjects with genotype-1 chronic hepatitis C. Presented at: 44th Annual Meeting of the European Association for the Study of the Liver; April 22-26, 2009; Copenhagen, Denmark. Abstract 4.
20. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50(2):387-392.
21. Kanwal F, Hoang T, Kramer JR, et al. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroentronology 2011;140(4):1182-1188.
22. Ghany MG, Strader DB, Thomas DL, Seeff LB. AASLD Practice guidelines: Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009; 49(4):1335-1374.
23. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-1069
24. Ong JP, Collantes R, Pitts A, et al. High rates of uninsured among HCV-positive individuals. J Clin Gastroenterol. 2005;39(9):826-830. EE